Investigation Report on China's Pregabalin Market 2021-2025

SKU ID : CRI- 18788984

Publishing Date : 19-Jul-2021

No. of pages : 50


  • Pregabalin is an ion channel modulator used to treat epilepsy, neuropathic pain, fibromyalgia, and generalized anxiety disorder. Its product, LYRICA was originally developed by Pfizer Ltd. LYRICA was launched in China in 2010 and was approved for the treatment of post-herpetic neuralgia. In 2018, it was approved for fibromyalgia indication. Subsequently, some generic drugs of Pregabalin were launched in China one after another. In 2019, Pregabalin (trade name: Laireike) produced by Chongqing Saiwei Pharmaceutical was approved for the treatment of adult partial epilepsy, adding a new indication for Pregabalin in the Chinese market. By 2020, Pregabalin has been included in China's Class B medical insurance, and there are three manufactures in the Chinese market, of which Pfizer Ltd is the main manufacture.

    According to Researcher, the sales value of Pregabalin in the Chinese market increased year by year from 2016 to 2020. Among them, the growth in sales value in 2019 was the most obvious. The sales value of Pregabalin reached CNY143 million in 2019, with an annual growth rate of 57.19%. The main reason is that Pregabalin was approved for new indications in China from 2018 to 2019, and the NMPA lifted the restriction on Pregabalin medical insurance indications in 2019, which led to a substantial increase in its sales volume and sales value. In 2020, the sales value of Pregabalin in the Chinese market is approximately CNY186 million. The CAGR in sales value of Pregabalin from 2016 to 2020 is 40.55%.

    Researcher expects that with the addition of new companies, the sales volume and market scale of Pregabalin in the Chinese market will continue to expand from 2021 to 2025. According to CRI’s market research, by the first half of 2021, there are more than 20 companies in China that are applying for Pregabalin generic drugs, including Jiangsu Hengrui Pharmaceutical Co., Ltd., Xuzhou Enhua Pharmaceutical Co., Ltd., and Sichuan Kelun Pharmaceutical Co., Ltd. In addition, China has approved the marketing of 3 indications of Pregabalin, and a total of 4 indications have been approved for marketing globally. Therefore, the number of indications of Pregabalin in China is likely to increase, and sales value and sales volume will increase in the future.


    Topics Covered:

    • -The impact of COVID-19 on China's Pregabalin market

    • - Sales value of China's Pregabalin 2016-2020

    • - Competitive landscape of China's Pregabalin market

    • - Prices of Pregabalin in China

    • - Prices of Pregabalin in China by regions and manufacturers

    • - Analysis on factors affecting the development of China's Pregabalin market

    • - Prospect of China's Pregabalin market from 2021 to 2025

    Frequently Asked Questions

    This market study covers the global and regional market with an in-depth analysis of the overall growth prospects in the market. Furthermore, it sheds light on the comprehensive competitive landscape of the global market. The report further offers a dashboard overview of leading companies encompassing their successful marketing strategies, market contribution, recent developments in both historic and present contexts.

    • By product type
    • By End User/Applications
    • By Technology
    • By Region

    The report provides a detailed evaluation of the market by highlighting information on different aspects which include drivers, restraints, opportunities, and threats. This information can help stakeholders to make appropriate decisions before investing.
    market Reports market Reports